Search
Taragarestrant
go.drugbank.com/drugs/DB21574InvestigationalTaragarestrant has a monoisotopic molecular weight of 474.13 Da. … Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).
Tezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
AEM-28
go.drugbank.com/drugs/DB17642InvestigationalAEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]
ISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalIt was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.
Muvalaplin
go.drugbank.com/drugs/DB21568InvestigationalMuvalaplin has a monoisotopic molecular weight of 710.4 Da. … Muvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events).
Benzbromarone
go.drugbank.com/drugs/DB12319ApprovedWithdrawnBenzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
ATL1102
go.drugbank.com/drugs/DB04997InvestigationalATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
ATG003
go.drugbank.com/drugs/DB05069InvestigationalATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.